MET gene is located on chromosome 7q31.2 and encodes a transmembrane tyrosine kinase receptor. The ligand of MET is hepatocyte growth factor (HGF), which is secreted by mesenchymal cells. The binding of HGF and c-MET can promote cell proliferation, migration, differentiation and morphological changes. The HGF/c-MET signaling pathway is highly regulated and plays an important role in cell proliferation, differentiation and movement.
MET gene amplification probe uses orange-red dye to label MET gene region, and green dye to label chromosome 7 centromere region (CEP7). MET gene marker region is located at 7q31.2, and the CEP7 probe is labeled with a specific alpha satellite sequence.
MET gene can be amplified in a variety of tumors such as lung cancer, breast cancer, ovarian cancer, thyroid cancer, gastric cancer, colorectal cancer, etc. It is an independent prognostic factor, and the prognosis of patients with MET gene amplification is poor. In NSCLC, MET gene amplification is closely related to poor prognosis and TKIs drug resistance.
MET gene amplification is one of the targets of XALKORI (Crizotinib). Tumors in patients with MET gene amplification can shrink significantly after treatment.
Product size: 100μL FISH probe ( ⬤ | ⬤ ) + Pretreatment reagent (10 tests) + Antifade staining solution DAPI (10 tests).